Porous Calcium Phosphate Injectable Fillers for Tissue Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dermal and subdermal fillers lack biocompatibility, consistency, and long-term efficacy, often causing adverse effects and requiring frequent retreatments due to limited duration of action and potential for migration or nodulation.
Innovation Solution
A biocompatible injectable filler composition comprising porous calcium phosphate particles with a small particle size and a thermoreversible gelling agent, which provides improved flexibility and prolonged duration of effect by forming a stable matrix upon injection, allowing for tissue augmentation with reduced irritation and increased persistence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional dermal fillers are used, then immediate results are achieved, but duration of action is limited requiring frequent retreatment
Solution Approach 1:
The patent changes the chemical composition parameters by incorporating calcium phosphate particles with specific surface area (1-100 m2/g) and porosity (10-90%) combined with thermoreversible gelling agents. This parameter modification enables the filler to maintain structural integrity and biological activity for extended periods (6-12 months or more), directly resolving the contradiction between immediate results and long-lasting effect.
Solution Approach 2:
The invention uses a composite material system combining calcium phosphate particles with thermoreversible gelling agents (such as hyaluronic acid, collagen, or synthetic polymers). This composite structure provides both immediate volumetric effect and prolonged duration of action, eliminating the need for frequent retreatment while maintaining safety and biocompatibility.
2Reliability
If filler particles are made larger to avoid phagocytosis, then biocompatibility improves, but particle size increases affecting injection characteristics
Solution Approach 1:
The patent optimizes particle size parameters to a specific range (1-30 microns) with controlled surface area (1-100 m2/g) and porosity (10-90%). This parameter optimization allows particles to be small enough for easy injection while large enough to avoid phagocytosis, resolving the contradiction between biocompatibility and injectability.
Solution Approach 2:
The invention employs porous calcium phosphate particles with controlled porosity (10-90%) that provide internal surface area for biological interaction while maintaining external dimensions suitable for injection. The porous structure enables biocompatibility through controlled degradation and integration without requiring excessively large particle sizes.
3Duration of action of moving object
If filler provides long duration of effect, then retreatment frequency decreases, but risk of nodules and hard lumps increases
Solution Approach 1:
The patent modifies physical parameters including particle size distribution, porosity (10-90%), and surface area (1-100 m2/g) to achieve long duration of effect without nodulation. The controlled porosity and surface area parameters prevent aggregation and ensure smooth integration into tissue, maintaining longevity while avoiding harmful side effects.
Solution Approach 2:
The invention applies local quality control by ensuring uniform distribution of calcium phosphate particles within the gel matrix and consistent particle size distribution (1-30 microns). This local homogeneity prevents localized aggregation and nodule formation while maintaining prolonged duration of effect throughout the treatment area.
4Reliability
If filler composition is made more complex to improve biocompatibility, then adverse effects decrease, but manufacturing complexity increases
Solution Approach 1:
The patent uses a relatively simple composite system of calcium phosphate particles combined with thermoreversible gelling agents that can be manufactured using standard techniques. The composite structure achieves high biocompatibility through the natural degradation and integration properties of these materials without requiring complex manufacturing processes or specialized equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The filler composition achieves long-lasting tissue augmentation with minimal adverse effects, maintaining volume and texture for 6 months or more without significant loss, reducing the need for frequent treatments and minimizing complications like nodules or hard lumps.
Implementation Method 1
a thermoreversible gelling agent that is nontoxic, provides improved flexibility, and a long duration of effect
Implementation Method 2
porous calcium phosphate particles having a small particle size in combination with a thermoreversible gelling agent
Data Source
AI summary
The present invention relates to a biocompatible injectable filler composition comprising calcium phosphate particles having a porosity of about 10% to about 90%, a BET surface area of about 1 m2/g to about 100 m2/g, and a mean particle size of about 1 micron to about 30 microns, a thermoreversible hydrophilic gelling agent, a carrier comprising water and an optional persistence enhancer and/or volumizing agent, and methods of its use to restore tissue volume and/or to smooth out tissue defects as in soft tissue or deep tissue augmentation.